Rigel Pharmaceuticals (RIGL) Competitors $28.84 +0.44 (+1.56%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. MNKD, CLDX, NVAX, BCRX, OPK, DVAX, INVA, ZBIO, GERN, and MYGNShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), Zenas BioPharma (ZBIO), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Its Competitors MannKind Celldex Therapeutics Novavax BioCryst Pharmaceuticals OPKO Health Dynavax Technologies Innoviva Zenas BioPharma Geron Myriad Genetics Rigel Pharmaceuticals (NASDAQ:RIGL) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Do institutionals and insiders believe in RIGL or MNKD? 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 9.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to RIGL or MNKD? In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than MannKind. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 11 mentions for MannKind. MannKind's average media sentiment score of 1.05 beat Rigel Pharmaceuticals' score of 0.05 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, RIGL or MNKD? MannKind has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$267.92M1.93$17.49M$5.415.33MannKind$301.74M4.92$27.59M$0.1143.95 Do analysts prefer RIGL or MNKD? Rigel Pharmaceuticals presently has a consensus target price of $38.20, suggesting a potential upside of 32.44%. MannKind has a consensus target price of $10.86, suggesting a potential upside of 124.55%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29MannKind 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is RIGL or MNKD more profitable? Rigel Pharmaceuticals has a net margin of 36.51% compared to MannKind's net margin of 10.87%. Rigel Pharmaceuticals' return on equity of 438.89% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals36.51% 438.89% 57.03% MannKind 10.87%-32.60%7.81% Which has more volatility & risk, RIGL or MNKD? Rigel Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. SummaryMannKind beats Rigel Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$513.34M$2.60B$6.03B$10.35BDividend YieldN/A56.68%5.66%4.69%P/E Ratio5.2923.0885.4326.75Price / Sales1.93624.91584.59179.25Price / Cash26.66177.3038.3262.20Price / Book151.815.4212.766.61Net Income$17.49M$32.78M$3.30B$275.78M7 Day Performance1.07%3.48%1.60%-0.43%1 Month Performance-20.93%11.38%8.18%6.31%1 Year Performance89.39%0.73%80.39%33.17% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals3.6821 of 5 stars$28.84+1.6%$38.20+32.4%+88.0%$513.34M$267.92M5.29160Analyst ForecastMNKDMannKind4.0519 of 5 stars$5.66-1.7%$11.17+97.3%-20.1%$1.77B$301.74M51.46400News CoveragePositive NewsAnalyst ForecastCLDXCelldex Therapeutics2.0961 of 5 stars$26.38-0.1%$46.13+74.8%-8.5%$1.75B$7.02M-8.76150Positive NewsAnalyst ForecastNVAXNovavax4.2696 of 5 stars$9.08-4.0%$14.29+57.3%-32.3%$1.54B$682.16M3.981,990Analyst ForecastBCRXBioCryst Pharmaceuticals4.0995 of 5 stars$7.02-1.8%$16.30+132.2%+0.0%$1.50B$450.71M-39.00530Analyst ForecastOPKOPKO Health4.34 of 5 stars$1.58+1.3%$2.63+66.1%+4.0%$1.24B$713.10M-6.322,997Analyst ForecastDVAXDynavax Technologies4.5052 of 5 stars$10.14+0.4%$24.33+140.0%-2.3%$1.18B$277.25M-22.04350Positive NewsAnalyst ForecastINVAInnoviva4.7844 of 5 stars$17.42-0.3%$37.60+115.8%-11.2%$1.10B$358.71M56.20100Analyst ForecastZBIOZenas BioPharma2.4813 of 5 stars$23.03+5.8%$36.67+59.2%N/A$916.32M$5M0.00N/ATrending NewsAnalyst ForecastInsider TradeGap UpGERNGeron2.5194 of 5 stars$1.28-5.2%$3.79+195.8%-67.1%$861.32M$76.99M-9.8570News CoverageAnalyst ForecastMYGNMyriad Genetics3.7808 of 5 stars$7.99-0.9%$12.45+55.9%-68.2%$749.94M$837.60M-1.872,700 Related Companies and Tools Related Companies MannKind Alternatives Celldex Therapeutics Alternatives Novavax Alternatives BioCryst Pharmaceuticals Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Zenas BioPharma Alternatives Geron Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsoleteWhen a new chip can run at the speed of light, the game changes. This is the reality of “TF3” — a man-made...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
